Mangalam Drugs & Organics Limited

NSE MANGALAM.NS

Mangalam Drugs & Organics Limited Net Income for the year ending March 31, 2024: USD -1.09 M

Mangalam Drugs & Organics Limited Net Income is USD -1.09 M for the year ending March 31, 2024, a -803.86% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

Mangalam Drugs & Organics Limited Net Income for the year ending March 31, 2023 was USD 154.52 K, a -94.03% change year over year.
Mangalam Drugs & Organics Limited Net Income for the year ending March 31, 2022 was USD 2.59 M, a -32.23% change year over year.
Mangalam Drugs & Organics Limited Net Income for the year ending March 31, 2021 was USD 3.82 M, a 248.82% change year over year.
Mangalam Drugs & Organics Limited Net Income for the year ending March 31, 2020 was USD 1.10 M, a 194.76% change year over year.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

NSE: MANGALAM.NS

Mangalam Drugs & Organics Limited

CEO	Mr. Govardhan Murlidhar Dhoot
IPO Date	May 23, 2005
Location	India
Headquarters	Rupam Building
Employees	432
Sector	Healthcare
Industries Pharmaceuticals Chemicals & Advanced Materials Cleaning Supplies Drugstores & Retail Pharmacies Personal Care Petrochemicals

Description

Mangalam Drugs & Organics Limited manufactures and sells drugs, medicines, and allied products in India and internationally. It offers a range of active pharmaceutical ingredients, intermediates, and specialty chemicals, as well as impurities for use in anti-malarial, analgesic/anti-inflammatory, anti-hypertensive, and anti-retroviral applications. The company was incorporated in 1972 and is based in Mumbai, India.

Key trends

Past 5 years